Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | WDR5 | P61964 | 2/20 | 0.37 |
| ▸ | BRS3 | P32247 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ATP1A1 | P05023 | 2/20 | 0.37 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.37 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.37 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.37 |
| ▸ | ATP4A | P20648 | 2/20 | 0.37 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.37 |
| ▸ | ATP4B | P51164 | 2/20 | 0.37 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.37 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.37 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7008064 | 0.94 | CYP2C9 (0.42) | CYP2C9KMT2AMEN1ALDH1A1HTT | |
| Agn-201904 SCHEMBL2510925 | 0.93 | CYP2C9 (0.41) | CYP2C9KMT2AMEN1ALDH1A1HTT | |
| Agn-201904 SCHEMBL2245875 | 0.93 | CYP2C9 (0.41) | CYP2C9KMT2AMEN1ALDH1A1HTT | |
| Agn-201904 SCHEMBL5764653 | 0.93 | CYP2C9 (0.41) | CYP2C9KMT2AMEN1ALDH1A1HTT | |
| Agn-201904 SCHEMBL5330690 | 0.93 | CYP2C9 (0.41) | CYP2C9KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL12353538 | 0.93 | CYP2C9 (0.41) | CYP2C9KMT2AMEN1ALDH1A1HTT | |
| Agn-201904 SCHEMBL29596867 | 0.93 | CYP2C9 (0.41) | CYP2C9KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL7223820 | 0.93 | CYP2C9 (0.38) | CYP2C9KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL14495756 | 0.92 | CYP2C9 (0.40) | CYP2C9KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL5368641 | 0.92 | CYP2C9 (0.40) | CYP2C9KMT2AMEN1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559167-B1 | Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-06 | — | — | US | claimed |
| EP-1105387-B1 | PRODRUGS OF PROTON PUMP INHIBITORS | WINSTON PHARMATEUTICALS LLC (US) | 2003-01-29 | — | — | EP | claimed |
| US-20100317689-A1 | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety | ALEVIUM PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100113524-A1 | Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety | ALEVIUM PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-6559167-B1 | Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-06 | — | — | US | disclosed |
| EP-1105387-B1 | PRODRUGS OF PROTON PUMP INHIBITORS | WINSTON PHARMATEUTICALS LLC (US) | 2003-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317689-A1 | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety | ABCB11, ATP6AP1, CYP4B1 | CYP2C9 44/4885KMT2A 1889/4885MEN1 1745/4885 |
| US-20100113524-A1 | Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety | ABCB11, ATP6AP1, PAH | CYP2C9 88/4885KMT2A 2644/4885MEN1 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.